Making medical decisions is not as easy as following the evidence. When dealing with people, there are a number of anomalies that influence the decisions someone might make.
Making medical decisions is not as easy as following the evidence. When dealing with people, there are a number of anomalies that influence the decisions someone might make, explained Douglas E. Hough, PhD, from Johns Hopkins University, during a plenary session at ISPOR’s annual meeting.
Hough outlined the thought processes that impact someone’s decisions or behaviors and the implications behavioral economics could have in healthcare. He provided 5 examples of anomalies that influence behavior:
These all influence things in healthcare, such as how we fight obesity, how adherent we are to medication, physician engagement and hand offs in the emergency room, and more, Hough concluded.
Kevin Volpp, MD, PhD, of the University of Pennsylvania, discussed the 5000-hour problem, whereby even for patients with a chronic illness who see their doctor multiple times a year, there are 5000-plus hours where these patients are largely on their own. Technology is creating an enormous opportunity for population health, but it cannot work on its own.
“While the technology creates enormous new opportunities in this space, just giving people these devices by themselves is unlikely to change their behavior,” he said. “People who buy these [devices] are typically those who are already motivated and thinking about their health.”
The devices need to be part of a larger ecosystem where patients have a device that uploads information to a health system’s services and either the patient or a social supporter and the provider gets feedback and the information goes into the electronic medical record.
What will ultimately drive change, though? The relationship, said David Meltzer, MD, PhD, of University of Chicago. The literature on patient-doctor relationships has shown the importance of trust, interpersonal relationships, communication, and knowledge of the patient in the form of lower costs and better outcomes.
Ovarian Cancer Survival Gaps Persist Across Racial, Ethnic Groups
May 27th 2025Abstracts published ahead of the 2025 American Society of Clinical Oncology Annual Meeting found persistent ovarian cancer survival disparities among racial and ethnic subgroups, particularly within disaggregated Asian American, Native Hawaiian, and Pacific Islander populations.
Read More
The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD
May 21st 2025The advent of novel cancer care therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies is transforming the role of pharmacists in enhancing patient care.
Read More
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD
May 17th 2025Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Read More